Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 5, 2020

View Archived Issues

Another reason to get a flu shot

Cerebrospinal fluid is early culprit in stroke edema

A pan-RAS antibody effectively inhibits in vitro and in vivo growth of RAS mutant-dependent tumors

Single-cell analysis of uveal melanoma TME identifies LAG3 as a candidate for checkpoint blockade

Gene transfer-mediated expression of anti-pTau Ab in the CNS for chronic traumatic encephalopathy

Agmatine is decreased in sepsis and may be a clinical biomarker and therapeutic agent

Saroglitazar approved in India as add on treatment for type 2 diabetes

First patient dosed in phase II study of AKST-4290 in in Parkinson's disease

AskBio doses first patient in phase I study of NAN-101

Novel motheaten spontaneous mutation mouse model of otitis media

Phase I/II data presented for Pexa-Vec plus durvalumab in CRC

Phase II study of SHR-1210 plus gemcitabine and oxaliplatin meets primary endpoint in BTC

Alkermes Pharma presents new naltrexone prodrugs for drug dependency

Heparegenix identifies MAP2K4 inhibitors

Medshine Discovery synthesizes new FGFR and HGFR inhibitors

Esteve Pharmaceuticals presents new analgesics

Chiesi Farmaceutici divulges new ROCK inhibitors

Researchers cast wide net for rapid-draw weapons in 2019-nCoV fight

Regeneron expands agreement with HHS to develop treatments for 2019-nCoV

Phase II data presented for lenvatinib plus pembrolizumab in patients with advanced gastric cancer

Hoth Therapeutics begins preclinical gene therapy study for asthma and allergic inflammation

Long-lasting responses seen with regorafenib plus nivolumab in REGONIVO study

FDA issues EUA for CDC's 2019-nCoV Real-Time RT-PCR Diagnostic Panel